

Publication

EP 0871449 A4 19981021

Application

EP 96912400 A 19960212

Priority

- CA 2199615 A 19960212
- US 9601990 W 19960212

Abstract (en)

[origin: WO9728803A1] Analogs of erythro-hydroxynonyladenine (EHNA) are disclosed which have been modified by bonding various types of moieties to the #8 or #9 carbon atoms in the "side chain" portion of the molecule. The compounds inhibit the intracellular enzymatic activity of adenosine deaminase and are therapeutically effective in reducing hypoxic and ischemic damage in heart and brain tissue.

IPC 1-7

A61K 31/52

IPC 8 full level

A61K 31/52 (2006.01)

CPC (source: EP)

A61K 31/52 (2013.01)

Citation (search report)

- [X] BE 826935 A 19750922
- [A] WO 9417809 A1 19940818 - GENSLA INC [US]
- [E] US 5491146 A 19960213 - ABUSHANAB ELIE [US]
- [X] SCHAEFFER ET AL.: "Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines", J. MED. CHEM., vol. 17, no. 1, 1974, pages 6 - 8, XP002060875
- [A] VERGESE ET AL.: "Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine", J. MED. CHEM., vol. 37, no. 22, 28 October 1994 (1994-10-28), pages 3844 - 3849, XP002060876
- [A] PHILLIS ET AL.: "Adenosine deaminase inhibitors enhance cerebral anoxic hyperemia in the rat", J. CEREBR. BLOOD FLOW METAB., vol. 5, no. 2, 1985, pages 295 - 299, XP002060877
- See references of WO 9728803A1

Designated contracting state (EPC)

AT BE CH DE ES FR GB IT LI NL SE

DOCDB simple family (publication)

WO 9728803 A1 19970814; AU 5522996 A 19970828; CA 2199615 A1 19970814; EP 0871449 A1 19981021; EP 0871449 A4 19981021

DOCDB simple family (application)

US 9601990 W 19960212; AU 5522996 A 19960212; CA 2199615 A 19960212; EP 96912400 A 19960212